BEGIN:VCALENDAR
VERSION:2.0
PRODID:icalendar-ruby
CALSCALE:GREGORIAN
X-WR-CALNAME:Histotripsy Cancer Treatment: The Road from Bench to Bedside
X-WR-TIMEZONE:Eastern Time (US & Canada)
BEGIN:VEVENT
DTSTAMP:20260910T215828Z
UID:tag:localist.com\,2008:EventInstance_46065050645847
DTSTART:20240417T160000Z
DTEND:20240417T170000Z
DESCRIPTION:Histotripsy Cancer Treatment: The Road from Bench to Bedside\n\
 nZhen Xu\, PhD.\n\nProfessor of Biomedical Engineering\, Radiology\, and N
 eurosurgery\, \n\nUniversity of Michigan\n\n \n\nHistotripsy is a non-inva
 sive\, non-ionizing\, and mechanical ultrasound ablation technique that wa
 s invented by Dr. Xu and her colleagues at the University of Michigan. Usi
 ng microsecond-length\, high-pressure ultrasound pulses applied from outsi
 de the body and focused to the target diseased tissue\, histotripsy produc
 es a cluster of energetic cavitation microbubbles in the target tissue usi
 ng the endogenous nanometer gas pockets. The rapid expansion and collapse 
 of the cavitation microbubbles produce high local mechanical strain and st
 ress to disrupt the target tissue into liquid-appearing acellular debris w
 ith millimeter accuracy. Pre-clinical studies have shown that ultrasound i
 mage-guided histotripsy can noninvasively and mechanically disrupt the tar
 get tumor while preserving the large normal vessels and other critical str
 uctures (e.g.\, bile ducts). Histotripsy tumor ablation results in tumor r
 eduction or complete eradication\, increased survival benefit\, and reduce
 d metastasis (abscopal effect). Histotripsy also induces significant innat
 e and adaptive immune response and abscopal effect in murine tumor models.
  Dr. Xu is a pioneer and leader of histotripsy and co-founder of HistoSoni
 cs. Her work has led to the FDA approval of non-invasive liver tumor treat
 ment using the EdisonTM ultrasound image-guided robotic assisted histotrip
 sy platform (HistoSonics)\, which is based on the technology licensed from
  Dr. Xu’s lab. In addition\, there are ongoing multi-center clinical tri
 als in the U.S. and Europe on histotripsy treatment of renal tumors using 
 the EdisonTM system. Dr. Xu will talk about the mechanism and instrumentat
 ion of histotripsy\, the latest pre-clinical and clinical progress on hist
 otripsy cancer treatment\, and her journal to bring this technology from b
 ench to bedside.  \n\n \n\nZhen Xu is Professor of Biomedical Engineering\
 , Radiology\, and Neurosrugery at the University of Michigan\, Ann Arbor\,
  MI. Her research focuses on ultrasound therapy and imaging\, particularly
  histotripsy. She is a pioneer and leader of histotripsy\, a non-invasive 
 mechanical therapeutic ultrasound technology based on cavitation. She has 
 developed histotripsy for cancer\, neurological\, and cardiovascular appli
 cations. Her work has led to the FDA approval of histotripsy treatment of 
 liver tumors. She received the IEEE Ultrasonics\, Ferroelectrics\, and Fre
 quency Control (UFFC) Outstanding Paper Award in 2006\; National Institute
  of Health (NIH) New Investigator Award at the First National Institute of
  Biomedical Imaging and Bioengineering (NIBIB) Edward C. Nagy New Investig
 ator Symposium in 2011\, The Frederic Lizzi Early Career Award from The In
 ternational Society of Therapeutic Ultrasound (ISTU) in 2015\, the Fellow 
 of American Institute of Medicine and Bioengineering (AIMBE) in 2019\, and
  The Lockhart Memorial Prize for Cancer Research in 2020\, and the Univers
 ity of Michigan Distinguished Innovator Award in 2023. She is an associate
  editor for IEEE Transactions on UFFC and Frontiers in Biomedical Engineer
 ing. She has served as the VP of IEEE Ultrasonics and an elected board mem
 ber of ISTU. She is a principal investigator of grants funded by NIH\, Off
 ice of Navy Research\, American Cancer Association\, and Focused Ultrasoun
 d Foundation. She has 40+ issued US and international patents and is a co-
 founder of HistoSonics\, a startup company developing histotripsy for onco
 logical applications. HistoSonics has raised $200+ millions with 120+ empl
 oyees.
GEO:43.126069;-77.629191
LOCATION:Wegmans Hall\, 1400
SUMMARY:Histotripsy Cancer Treatment: The Road from Bench to Bedside
URL;VALUE=URI:https://events.rochester.edu/event/histotripsy-cancer-treatme
 nt-the-road-from-bench-to-bedside
CATEGORIES:Lectures & Talks
END:VEVENT
END:VCALENDAR